Tenalisib (RP6530) is a novel, highly specific dual phosphoinositide-3 kinases (PI3K) δ/γ inhibitor with nano-molar potency. It demonstrated acceptable safety up to 1200 mg twice a day with no dose-limiting toxicities in patients with relapsed/refractory hematologic malignancies. Consistent clinical response was seen at doses 200 mg and above. Further phase I/II studies are being undertaken to evaluate efficacy across different histologies.

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study / Carlo-Stella, C.; Delarue, R.; Scarfo', L.; Barde, P. J.; Nair, A.; Locatelli, S. L.; Morello, L.; Magagnoli, M.; Vakkalanka, S.; Viswanadha, S.; Ferreri, A. J. M.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - 20:2(2020), pp. 78-86. [10.1016/j.clml.2019.10.013]

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study

Scarfo' L.;Ferreri A. J. M.
2020-01-01

Abstract

Tenalisib (RP6530) is a novel, highly specific dual phosphoinositide-3 kinases (PI3K) δ/γ inhibitor with nano-molar potency. It demonstrated acceptable safety up to 1200 mg twice a day with no dose-limiting toxicities in patients with relapsed/refractory hematologic malignancies. Consistent clinical response was seen at doses 200 mg and above. Further phase I/II studies are being undertaken to evaluate efficacy across different histologies.
2020
Dose escalation
Dose limiting toxicity
pAKT
Phase I
Tumor microenvironment
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/106396
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact